You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. X-Ray Detectors for Synchrotron-Based Structural Biology

    SBC: AREA DETECTOR SYSTEMS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Development is proposed of an x-ray Pixel Array Detector (PAD) consisting approximately of 2,000 x 2,000 pixels to enhance macromolecular crystallographic data collection at synchrotron sources. A PAD consists of an x-ray sensing integrated circuit layer bonded to a pixel electronics layer such that each pixel has its own processing electronics. PADs promise t ...

    SBIR Phase II 2003 Department of Health and Human Services
  2. A Tunable, Tabletop, Synchrotron Light Source

    SBC: LYNCEAN TECHNOLOGIES, INC.            Topic: N/A

    N/A

    SBIR Phase II 2003 Department of Health and Human Services
  3. Development of Fludase for Prevention of Influenza

    SBC: Nexbio, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Influenza is characterized by recurrent annual epidemics and periodic major worldwide pandemics. Because of the high disease-related morbidity and mortality, direct and indirect socio-economic impacts of influenza are enormous. In the last 100 years, there have been 3 major influenza pandemics. It has been about thirty years since the last pandemic. A new pand ...

    SBIR Phase II 2005 Department of Health and Human Services
  4. Prophylactic Anthrax Toxin Vaccine

    SBC: VICAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Vical Inc. seeks SBIR Phase II funding to develop and produce a licensable prophylactic anthrax vaccine. This project will move on an accelerated but realistic timeline with plans for human clinical trials to begin in September 2003. Although many candidate vaccines are being studied for anthrax prevention or post-exposure prophylaxis, the Vical approach has ...

    STTR Phase II 2003 Department of Health and Human Services
  5. CMV Immunotherapeutic Vaccine

    SBC: VICAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Vical Inc. of San Diego, Ca. is the largest GMP manufacturer of plasmid DNA for vaccine clinical trials in the world. We have manufactured GMP plasmid DNA vaccines that are being used or entering clinical trials for HIV (in the US and China), malaria (up to 9 plasmids), Ebola, WNV, and SARS. Vical has undertaken an internal Product Development Program that focu ...

    SBIR Phase II 2005 Department of Health and Human Services
  6. Genome-Wide Scan for Alzheimer's Associated Genes

    SBC: Perlegen Sciences, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this study is to identify the genetic determinants of late-onset Alzheimer's disease (AD). The proposed study uses Perlegen Sciences' high-density oligonucleotide array-based genotyping platform to genotype over 1.5 million single nucleotide polymorphisms (SNPs) across the genome in the context of a whole-genome association study of late-onset AD. ...

    SBIR Phase II 2005 Department of Health and Human Services
  7. Inhibition of hepatitis C by RNA-based therapeutics

    SBC: Somagenics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Treatment and prevention of hepatitis C virus (HCV) infections remains a major challenge for controlling this worldwide health problem; existing therapies are only partially effective and no vaccine is currently available. RNA interference offers the potential of a novel therapeutic approach for treating HCV infections. Toward this end, we are developing small ...

    SBIR Phase II 2005 Department of Health and Human Services
  8. PNA for Stroke

    SBC: SYNZYME TECHNOLOGIES LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Stroke is the 3rd leading cause of death in the U.S. and is also a leading cause of severe, long-term disability. The total cost of stroke to the United States is estimated at about $43 billion per year. The only FDA-approved treatment for acute ischemic stroke is recombinant tissue plasminogen activator (rt- PA). However, the therapeutic window of rt-PA is on ...

    SBIR Phase II 2005 Department of Health and Human Services
  9. A Novel Technology to Improve HIV Medication Compliance

    SBC: LIFETECHNIQUES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Infection with the human immunodeficiency virus (HIV) has led to one of the most costly and devastating epidemics of the last two decades. Untreated, the virus slowly destroys the immune system, leading to significant morbidity and virtually 100% mortality within two to twenty years after initial infection. Fortunately, recent advances in antiretroviral therap ...

    SBIR Phase II 2005 Department of Health and Human Services
  10. ALLOGENEIC TGF-B ANTISENSE CELL VACCINE FOR LUNG CANCER

    SBC: NOVARX CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): The purpose of this study is to conduct a Phase II clinical trial in patients with incurable non-small cell lung cancer (NSCLC). Our aim is to induce antitumor immune responses by immunizing patients with an experimental vaccine comprised of four allogeneic NSCLC cell lines genetically modified with a TGFbeta 2 antisense vector. By blocking secretion of the imm ...

    SBIR Phase II 2003 Department of Health and Human Services
US Flag An Official Website of the United States Government